Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• The bone marrow (BM) is a complex microenvironment essential for blood cell formation.
• Inflammation in the BM can trigger stress hematopoiesis but chronic inflammation impairs hematopoietic stem cell (HSC) function, promoting mutations and hematologic malignancies like myelodysplastic syndromes (MDS).
• The BM immune microenvironment (IME) significantly influences disease initiation and progression.

Purpose of the Study:

• To review the role of immune response mediators in the pathogenesis and evolution of MDS.
• To elucidate how the IME is reprogrammed in MDS to support dysplastic clones.
• To understand the transition from MDS to acute myeloid leukemia (AML) via immune evasion.

Main Methods:

• Literature review focusing on the interplay between inflammation, the BM IME, and MDS.
• Analysis of cellular and molecular mechanisms driving MDS pathogenesis.
• Examination of immune suppression and immune evasion strategies in MDS progression.

Main Results:

• Sustained inflammation in the BM impairs HSCs, favoring mutagenesis and MDS development.
• The MDS immune microenvironment (IME) is reprogrammed to support dysplastic clone survival and expansion, involving cells like myeloid-derived suppressor cells (MDSCs).
• Immune-mediated inhibition of normal hematopoiesis causes cytopenias in MDS patients.
• Late-stage MDS exhibits immunosuppression, facilitating immune evasion and progression to AML.

Conclusions:

• The BM immune microenvironment is a critical determinant in MDS pathogenesis and progression.
• Understanding immune mediators is key to targeting MDS and its evolution to AML.
• Therapeutic strategies targeting the IME may offer new avenues for MDS treatment.